Yousif Capital Management LLC Decreases Stock Holdings in Gilead Sciences, Inc. $GILD

by · The Cerbat Gem

Yousif Capital Management LLC lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 3.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 139,884 shares of the biopharmaceutical company’s stock after selling 4,999 shares during the quarter. Yousif Capital Management LLC’s holdings in Gilead Sciences were worth $15,527,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Norges Bank bought a new position in shares of Gilead Sciences in the 2nd quarter valued at about $2,150,268,000. Ameriprise Financial Inc. raised its position in Gilead Sciences by 397.6% during the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock valued at $748,147,000 after purchasing an additional 5,392,191 shares during the period. Invesco Ltd. raised its position in Gilead Sciences by 33.5% during the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after purchasing an additional 3,394,330 shares during the period. Assenagon Asset Management S.A. lifted its stake in shares of Gilead Sciences by 164.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock valued at $387,286,000 after purchasing an additional 2,169,266 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC purchased a new position in shares of Gilead Sciences in the 2nd quarter worth approximately $238,083,000. 83.67% of the stock is currently owned by institutional investors.

Insider Activity

In other Gilead Sciences news, Director Kelly A. Kramer sold 2,805 shares of Gilead Sciences stock in a transaction on Friday, November 28th. The stock was sold at an average price of $127.10, for a total transaction of $356,515.50. Following the completion of the sale, the director directly owned 1,339 shares of the company’s stock, valued at $170,186.90. The trade was a 67.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $126.54, for a total value of $1,265,400.00. Following the completion of the sale, the chief executive officer owned 571,203 shares of the company’s stock, valued at $72,280,027.62. This represents a 1.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 136,257 shares of company stock valued at $16,723,492. Insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on GILD. Wolfe Research restated an “outperform” rating and set a $150.00 price target on shares of Gilead Sciences in a report on Monday, December 15th. Morgan Stanley boosted their price objective on shares of Gilead Sciences from $147.00 to $151.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Truist Financial assumed coverage on shares of Gilead Sciences in a research note on Monday, November 24th. They issued a “buy” rating and a $140.00 target price on the stock. Argus lifted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Finally, Needham & Company LLC upped their price target on shares of Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $131.54.

Read Our Latest Report on GILD

Gilead Sciences Stock Down 0.1%

NASDAQ:GILD opened at $124.16 on Tuesday. The company has a market cap of $154.04 billion, a price-to-earnings ratio of 19.25, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32. Gilead Sciences, Inc. has a twelve month low of $88.57 and a twelve month high of $128.70. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The stock has a fifty day simple moving average of $122.47 and a 200-day simple moving average of $116.31.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the prior year, the business posted $2.02 earnings per share. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Featured Stories

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).